Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2009 1
2012 1
2013 1
2015 5
2016 6
2017 10
2018 4
2019 15
2020 17
2021 12
2022 3
2023 8
2024 12
2025 15
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean huang y[au] (95,311 results)?
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J. Song Y, et al. Among authors: shuang y. Lancet Oncol. 2024 Jan;25(1):117-125. doi: 10.1016/S1470-2045(23)00589-2. Epub 2023 Dec 9. Lancet Oncol. 2024. PMID: 38092009 Clinical Trial.
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database.
Yan Q, Bruni C, Garaiman A, Mihai C, Jordan S, Becker MO, Elhai M, Dobrota R, Liubov P, Henes J, Hachulla E, Siegert E, Balbir-Gurman A, Cuomo G, Riemekasten G, Heitmann S, Beigi DMR, Ullman S, Sfikakis P, Ingegnoli F, Bernardino V, Truchetet ME, Vonk M, Galdo FD, Hoffmann-Vold AM, Shuang Y, Distler O; EUSTAR collaborators. Yan Q, et al. Among authors: shuang y. Ann Rheum Dis. 2025 Apr;84(4):620-631. doi: 10.1016/j.ard.2025.01.014. Epub 2025 Feb 1. Ann Rheum Dis. 2025. PMID: 39894689
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study.
Deng L, Li Z, Zhang H, Huang H, Hu J, Liu L, Liu T, Jin J, Zhu Z, Li W, Huang Z, Huang W, Zhou K, Yang H, Zhang M, Ding K, Zhou H, Hu Y, Shuang Y, Cao J, Gao S, Li D, Sun Z, Zhang Q, Yi S, Ji C, Zhang L, Hou C, Du Y, Wang W, Zhao R, Song Y, Zhu J. Deng L, et al. Among authors: shuang y. Am J Hematol. 2023 Nov;98(11):1742-1750. doi: 10.1002/ajh.27064. Epub 2023 Aug 30. Am J Hematol. 2023. PMID: 37647123 Free article. Clinical Trial.
A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma.
Hong H, Chen Z, Zhang M, Peng Z, Shen J, Shuang Y, Zhou H, Guo H, Huang H, Li F, Qian Z, Liu L, Wang L, Yang W, Zhang L, He P, Qian S, Li F, Li M, Lin T. Hong H, et al. Among authors: shuang y. J Hematol Oncol. 2025 Apr 27;18(1):50. doi: 10.1186/s13045-025-01697-z. J Hematol Oncol. 2025. PMID: 40289142 Free PMC article. Clinical Trial.
Intelligent metasurface imager and recognizer.
Li L, Shuang Y, Ma Q, Li H, Zhao H, Wei M, Liu C, Hao C, Qiu CW, Cui TJ. Li L, et al. Among authors: shuang y. Light Sci Appl. 2019 Oct 21;8:97. doi: 10.1038/s41377-019-0209-z. eCollection 2019. Light Sci Appl. 2019. PMID: 31645938 Free PMC article.
[Retracted] Role of the EZH2/miR‑200 axis in STAT3‑mediated OSCC invasion.
Wang Y, Guo W, Li Z, Wu Y, Jing C, Ren Y, Zhao M, Kong L, Zhang C, Dong J, Shuang Y, Sun S, Chen J, Wu C, Qiao Y, Qu X, Wang X, Zhang L, Jin R, Zhou X. Wang Y, et al. Among authors: shuang y. Int J Oncol. 2025 May;66(5):34. doi: 10.3892/ijo.2025.5740. Epub 2025 Mar 21. Int J Oncol. 2025. PMID: 40116088 Free PMC article.
Machine-learning reprogrammable metasurface imager.
Li L, Ruan H, Liu C, Li Y, Shuang Y, Alù A, Qiu CW, Cui TJ. Li L, et al. Among authors: shuang y. Nat Commun. 2019 Mar 6;10(1):1082. doi: 10.1038/s41467-019-09103-2. Nat Commun. 2019. PMID: 30842417 Free PMC article.
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.
Cao J, Chen G, Qiu L, Zhang L, Jiang M, Cheng Y, Zhang Q, Liu L, Li P, Shuang Y, Wang H, Xue H, Wu H, Zheng M, Zhou K, Li Z, Jing H, Yang W, Zhu Z, Li W, Wangwu J, Huang H, Jia Q, Chen D, Fan S, Shi MM, Su W. Cao J, et al. Among authors: shuang y. EClinicalMedicine. 2025 Aug 18;87:103399. doi: 10.1016/j.eclinm.2025.103399. eCollection 2025 Sep. EClinicalMedicine. 2025. PMID: 40896460 Free PMC article.
97 results